Want to see CRVO full AI Analyst Report?
CRVO Stock Chart & Stats
$2.65
>-$0.01(-0.37%)
At close: 4:00 PM EDT
$2.65
>-$0.01(-0.37%)
Day’s Range― - ―
52-Week Range$2.13 - $10.00
Previous CloseN/A
Volume118.08K
Average Volume (3M)198.21K
Market Cap
$48.08M
Enterprise Value$6.82M
Total Cash (Recent Filing)$24.94M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.69
Next Earnings
Nov 16, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding15,119,096
10 Day Avg. Volume285,090
30 Day Avg. Volume198,205
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue21.14
Enterprise Value/Gross Profit21.14
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$15.50Price Target Upside484.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$266.67K
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt reduces fixed financial obligations and gives CervoMed greater flexibility while it advances clinical programs. Positive equity and an asset base provide some balance-sheet support, although future funding needs remain important for this development-stage company.
Improved Drug FormulationThe tablet and dosing work addresses formulation variability while the FDA change provides greater flexibility in future trial dosing. Together, these advances may reduce development and manufacturing risk and improve the program’s ability to reach later-stage testing.
Regulatory Development SupportThe Innovation Passport gives CervoMed access to UK regulators, health technology bodies, and the NHS, strengthening development coordination in an area with no approved treatments. This support may improve the company’s regulatory positioning as Phase 3 planning advances.
Bears Say
Minimal Commercial RevenueCervoMed has not yet demonstrated meaningful commercial scale, with minimal revenue unable to offset its research and development cost base. Large ongoing losses indicate that earnings power depends on successful clinical development and eventual regulatory approval.
Heavy Cash BurnSubstantial operating and free-cash-flow outflows mean CervoMed is consuming capital while its pipeline remains in development. Until revenue scales or spending moderates, the company is likely to remain dependent on external financing to sustain trials and operations.
Clinical Execution RiskThe failure to reproduce earlier Phase 2a benefits demonstrates that clinical outcomes remain uncertain despite encouraging subgroup and biomarker findings. The need to refine patient selection and exposure increases execution risk for the planned Phase 3 strategy.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $2.13 and its highest was $10.00 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $48.08M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Nov 16, 2026 which is in 38 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Aug 10, 2026. The company reported -$0.64 earnings per share for the quarter, beating the consensus estimate of -$0.839 by $0.199.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.49.
How many shares outstanding does CervoMed have?
CervoMed has 15,119,096 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.64 in its last earnings report, beating expectations of -$0.839. Following the earnings report the stock price went down -0.348%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (484.91% Upside)
$15.50 (484.91% Upside)
Blogger Sentiment
Bullish
CRVO Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 689.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.71%
12-Months-Change
Fundamentals
Return on Equity
-156.02%
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
CRVO Stock 12 Month Forecast
Average Price Target
$15.50
▲(484.91% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
33.30% Insiders
2.45% Mutual Funds
0.33% Other Institutional Investors
61.60% Public Companies and
Individual Investors